HEALTH CARE UTILIZATION AND COSTS AFTER WARFARIN DISCONTINUATION AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

被引：0
|
作者：
Wang, J. [1 ]
Qiao, Y. [1 ]
Spivey, C. A. [1 ]
Liu, X. [2 ]
Phatak, H. [3 ]
Mardekian, J. [4 ]
Claflin, A. B. [4 ]
Kachroo, S. [3 ]
Abdulsatter, Y. [4 ]
Parker, R. B. [1 ]
机构：
[1] Univ Tennessee, Coll Pharm, Memphis, TN USA
[2] Univ Tennessee, Coll Pharm, New York, NY USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.230
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV4
引用
收藏
页码：A756 / A756
页数：1
相关论文
共 50 条
  • [31] Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
    Breithardt, Guenter
    Baumgartner, Helmut
    Berkowitz, Scott D.
    Hellkamp, Anne S.
    Piccini, Jonathan P.
    Lokhnygina, Yuliya
    Halperin, Jonathan L.
    Singer, Daniel E.
    Hankey, Graeme J.
    Hacke, Werner
    Becker, Richard C.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Califf, Robert M.
    Fox, Keith A. A.
    Patel, Manesh R.
    [J]. HEART, 2016, 102 (13) : 1036 - 1043
  • [32] Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US
    Schoof, Nils
    Schnee, Janet
    Schneider, Gary
    Gawlik, Melissa
    Zint, Kristina
    Clemens, Andreas
    Bartels, Dorothee B.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (05) : 795 - 804
  • [33] Under-use of warfarin for patients with non-valvular atrial fibrillation in Japan
    Inoue, H
    [J]. INTERNAL MEDICINE, 2004, 43 (07) : 529 - 530
  • [34] Comparison of Stroke- and Bleed-Specific Healthcare Resource Utilization and Costs Among Patients with Non-Valvular Atrial Fibrillation, Newly Treated with Dabigatran or Warfarin
    Song, Xue
    Gandhi, Pranav
    Gilligan, Adrienne M.
    Arora, Prachi
    Henriques, Caroline
    Wang, Cheng
    Sander, Stephen
    Smith, David M.
    [J]. BLOOD, 2016, 128 (22)
  • [35] High burden of potentially avoidable stroke from discontinuation of warfarin therapy in non-valvular atrial fibrillation
    Freedman, S. B.
    Martinez, C.
    Wallenhorst, C.
    Katholing, A.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 862 - 862
  • [36] Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
    Coleman, Craig I.
    Tangirala, Muralikrishna
    Evers, Thomas
    [J]. PLOS ONE, 2016, 11 (06):
  • [37] Total health care costs of patients with chronic non-valvular atrial fibrillation before and after TIA, ischemic stroke or major bleed
    Stephenson, JJ
    Fernandes, J
    Beaulieu, JF
    Del Agulia, MA
    Hauch, O
    Kim, J
    Boccuzzi, SJ
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 263 - 263
  • [38] DEVELOPMENT OF A SHORT-TERM WARFARIN CONTROL MEASURE AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Shi, L.
    Liu, S.
    Zhao, Y.
    Irimpen, A. K.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (02) : 388 - 389
  • [39] Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view
    Xie, Lin
    Vo, Lien
    Keshishian, Allison
    Price, Kwanza
    Singh, Prianka
    Mardekian, Jack
    Bruno, Amanda
    Baser, Onur
    Kim, Jully
    Tan, Wilson
    Trocio, Jeffrey
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (08) : 769 - 776
  • [40] Correlation between primary care physicians' attitudes and the utilization of warfarin in nursing home patients (NHP) with non-valvular atrial fibrillation (NVAF).
    Thompson, JR
    Hanley, JF
    Tung, N
    Ladwig, JW
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S130 - S130
12345